| Field | Specification |
|---|---|
| Target | |
| Alternative names | 12 kDa FK506-binding protein; 12 kDa FKBP; Calstabin 1; FK506 binding protein 1; FK506 binding protein 12; FK506 binding protein 1A (12kD); FK506 binding protein 1A 12kDa; FK506 binding protein 1A; FK506 binding protein T cell 12 kD; FK506 binding protein; T cell; 12 kD; FK506 binding protein12; FK506-binding protein 1A; FKB1A_HUMAN; FKBP 12; FKBP 1A; FKBP-12; FKBP-1A; FKBP1; FKBP12; FKBP12 Exip3; FKBP12C; fkbp1a; Immunophilin FKBP12; Peptidyl prolyl cis trans isomerase; Peptidyl-prolyl cis-trans isomerase FKBP1A; PKC12; PKCI2; PPIase; PPIase FKBP1A; Protein kinase C inhibitor 2; Rotamase |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | Recombinant Human Peptidyl-prolyl cis-trans isomerase FKBP1A protein (2-103AA) |
| Conjugate | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Purification | |
| Form | Liquid |
| Storage | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
This is a polyclonal anti-FKBP1A antibody raised in Rabbit, conjugated with FITC. It is designed to detect FKBP1A protein in Human and supports researchers working in immunology contexts where consistent antibody performance is required.
Key elements and design rationale
- Immunogen: Recombinant Human Peptidyl-prolyl cis-trans isomerase FKBP1A protein (2-103AA) — the immunizing antigen determines the epitope region; confirm epitope compatibility with sample preparation and expected post-translational modifications.
- Host species (Rabbit): Requires anti-rabbit-IgG secondary reagents. Use matched secondaries to avoid no-signal or cross-reactivity issues.
- Polyclonal format: Recognizes multiple epitopes, providing robust signal across varied preparations and species variants. Inherent lot-to-lot variability requires appropriate controls.
- Isotype (IgG): Compatible with standard Protein A/G purification and widely supported by secondary reagents. Include an isotype-matched control at equivalent concentration.
- Purification (Protein G purification): Enriches for specific immunoglobulin classes, reducing non-specific populations and improving signal-to-noise.
- FITC conjugate: Direct fluorescence detection (Ex ~490/Em ~525 nm). FITC is photolabile; protect samples and use antifade reagents for slides.
Biological background
FKBP1A (also referred to as 12 kDa FK506-binding protein, 12 kDa FKBP, Calstabin 1, FK506 binding protein 1, FK506 binding protein 12, FK506 binding protein 1A (12kD), FK506 binding protein 1A 12kDa, FK506 binding protein 1A, FK506 binding protein T cell 12 kD, FK506 binding protein, T cell, 12 kD, FK506 binding protein12, FK506-binding protein 1A, FKB1A_HUMAN, FKBP 12, FKBP 1A, FKBP-12, FKBP-1A, FKBP1, FKBP12, FKBP12 Exip3, FKBP12C, fkbp1a, Immunophilin FKBP12, Peptidyl prolyl cis trans isomerase, Peptidyl-prolyl cis-trans isomerase FKBP1A, PKC12, PKCI2, PPIase, PPIase FKBP1A, Protein kinase C inhibitor 2, Rotamase) is a protein target studied in Human systems. Expression levels, subcellular localization, and post-translational modifications vary across cell types, tissues, and disease states — factors that influence antibody-based detection and experimental design. Consult UniProt, NCBI Gene, and primary literature for current annotation of FKBP1A biology, including known isoforms, interactors, and disease-relevant expression patterns in immunology.
Common research applications
- Refer to product documentation for confirmed application data and recommended conditions.
Notes for experimental interpretation
- Isotype controls: Use an isotype-matched (IgG from Rabbit) control at equivalent concentration to assess non-specific background.
- Cross-reactivity: Polyclonal preparations may cross-react with related proteins or isoforms. Orthogonal validation (siRNA, KO lysate, recombinant protein) is recommended to confirm signal specificity.
- Matrix effects: Sample matrix (serum, plasma, lysate, homogenate) can affect performance. Pilot dilution linearity and spike-recovery experiments are recommended for quantitative studies.
- Species reactivity: Confirmed for Human. Extrapolation to untested species requires empirical validation given potential epitope sequence divergence.
This product is a polyclonal antibody purified from rabbit antiserum.
FKBP1A is a protein target in Human biology. This polyclonal antibody raised in Rabbit is designed to detect FKBP1A in immunoassay applications, with IgG isotype.
This antibody is reported reactive against Human. The immunogen was derived from Human. Cross-reactivity with other species should not be assumed without documented data or empirical testing.
Application data were not specified; please consult the product datasheet or contact BioHippo support for confirmed application information.
FITC enables direct fluorescence detection (Ex ~490 nm/Em ~525 nm) without a secondary step. Protect from prolonged light exposure and use antifade mounting media for tissue sections.
Recommended: (1) Isotype control — IgG from Rabbit at matching concentration for non-specific background; (2) Positive control — known FKBP1A-expressing cell/tissue; (3) Negative control — knockdown or knockout sample to confirm signal specificity; (4) Dilution linearity — verify proportional signal decrease to confirm quantitative linearity in your matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
